Background and Aims: Concurrent chemotherapy plus radiation therapy (chemoRT) is an optimal and recommended treatment strategy for stage III non-small cell lung cancer (NSCLC) currently. Here, we sought to investigate the efficacy and safety of oral vinorelbine and cisplatin plus concomitant chemo-radiotherapy in treating stage III NSCLC patients.
Methods:
A prospective, open-label, single-arm clinical trial was performed during January 2010 to September 2016. Patients were treated with two cycles of chemotherapy with intravenous cisplatin 60 mg/m 2 on day 1 and oral vinorelbine 50 mg/m 2 on days 1, 8 and day 15, and radiotherapy was administrated concurrently since the day 1 when chemotherapy started. A total dose of 66 Gy radiotherapy was delivered in daily fractions of 2 Gy for 6.5-7 consecutive weeks. Tumor response will be assessed after completing 2 cycle of concomitant treatment, and patients were referred to surgery or consolidation therapy based on the assessment.
Results: Fifty-eight patients were enrolled and analyzed, 31 of the 56 patients had stage IIIA and the other 27 had stage IIIB NSCLC. Thirtysix patients had partial response (PR)to the therapy and the overall response rate was 62.1%. The median progression free survival (PFS) was 6.73 months and median overall survival (OS) was 24.83 months.
Seventeen patients received surgery after induction concurrent chemoradiation therapy (CCRT), and the median PFS was 25.67 months for patients received surgery. For safety, no adverse effects related mortality was recorded in this trial, and 20 patients ever experienced grade 3&4 neutropenia, and only one patient had febrile neutropenia. Forty-eight patients finally had complete treatment course of this trial, and the complete rate was 82.6%. Background and Aims: Lung cancer was a highly aggressive malignancy causing high morbidity and mortality. It was the leading cause of cancer-related deaths worldwide with an overall 5-year survival rate of 17% after diagnoses. Carcinoembryonic Antigen (CEA) marker, Computerized Tomography (CT) Scan imaging, bronchoscopy, and biopsy of bronchial brushing play an important role in the diagnosis of lung cancer. The aims of this study were to assess sensitivity and specificity of diagnostic modalities for lung cancer.
Methods: A retrospective study with descriptive analytic approach of 169 cases of suspected pulmonary mass that admitted to Wahidin Sudirohusodo Hospital Makassar Indonesia during January until December 2015. The patient were examined for CEA marker level, CT-scan imaging, bronchoscopy, and confirmed by biopsy of bronchial brushing. The correlations were assessed with statistical formula that analyzed by using SPSS 22.0.
Results: This Study predominantly male patients (72.7%), while mean age was 61 (24-97) years old. CEA level showed the significant correlation (P < 0.005) with poor sensitivity rate of 69,5% but high specificity rate of 96%. CT-scan imaging (P < 0.005) showed lower of sensitivity (44%) and specificity (89.7) rate compared with CEA marker. Bronchoscopic modalities carried the highest diagnostic yield (P < 0,005), with pooled sensitivity rate of 90% and specificity rate of 94%. The definitive diagnosis was established by biopsy of bronchial brushing.
Conclusion: Bronchoscopy showed potential for increasing the diagnostic yield of lung cancer with the highest sensitivity and specificity rate compare with the other modalities. The adequate tissue acquisition for histological and precise interpretation by expert from CT-scan imaging and bronchoscopy is very important to confirm diagnosis of lung cancer. 
